Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep…
Taiwan is, in many ways, a healthcare model for Asia. The island has had universal health coverage for over 30 years and Taiwan’s life expectancy today is almost 81 years,…
Vincent Tong, Managing Director of MSD Taiwan, brings two decades of pharmaceutical expertise to his second tenure leading the organisation in Taiwan. Having first served in Taiwan in 2008, Tong…
Professor Pan Chyr Yang is a clinician-scientist with an MD and PhD in pulmonary medicine, holding joint appointments at Academia Sinica and former university leadership roles in National Taiwan University. Recognised…
With its thriving innovation ecosystem and growing global visibility, Taiwan is fast emerging as one of Asia’s most dynamic biotechnology hubs. At the forefront of this transformation is Wallace Lin,…
Dr Chih-Kang Chiang, Director-General of the TFDA, shares how Taiwan is redefining regulation through science, transparency, and international collaboration. Combining his backgrounds in medicine, toxicology, and law, he leads efforts…
After more than two decades in Silicon Valley, Dr Jeng Her returned to Taiwan with a bold ambition: to help transform its emerging biotech sector into a globally recognised force…
Dr Wen-Liang Huang, General Manager of Ever Supreme Biotechnology, brings over 40 years of clinical cardiology experience to biopharmaceutical leadership. Recruited by the company’s founder, his medical background informs the…
Dr Chiu-Heng Chen (John), CEO of LaunXP, brings a unique perspective to oncology drug development shaped by his personal experience with cancer during his PhD in the UK. Holding advanced…
Taiwan’s healthcare system stands among the most advanced and accessible in Asia, yet, as the IRPMA’s CW Chen points out, sustainability is now the central concern. Drawing on a career…
Carl Wegner, President of AmCham Taiwan, reflects on his first months in the role, highlighting the chamber’s advocacy mission, the strength of its committees, growing US–Taiwan engagement, and major opportunities…
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
See our Cookie Privacy Policy Here
